Aiden Technology

About Aiden Technology

Aiden Technology, officially Tianjin Aiden Technology Co., Ltd., was established in 2016 by founder and CEO Zhu Wei. An MBA graduate from Rochester Institute of Technology who also studied at Capital Medical University, Zhu Wei previously founded the internet communication value assessment platform "Miaozhen" in 2007 before launching Aiden Technology.

The company operates as a medical big data and artificial intelligence firm, carving a niche in China's healthcare reform landscape. It focuses on applying AI and big data analytics, anchored in the principles of disease classification, to address inefficiencies within the healthcare system. The business model is centered on providing a comprehensive Diagnosis-Related Group (DRG) and Diagnosis-Intervention Packet (DIP) solution through a Software-as-a-Service (SaaS) platform to healthcare providers. This model generates revenue by helping hospitals and medical institutions improve operational efficiency, manage costs, and navigate the complexities of evolving healthcare payment reforms.

Aiden Technology serves a substantial client base, including nearly 4,000 second and third-tier medical institutions across China. Its core offering is the Aiden Hospital Collaborative Management Platform, which features the "Xingcan Engine," a data-driven SaaS system. This platform provides a suite of tools for medical record quality control, medical insurance settlement, cost accounting, performance evaluation, and clinical pathway analysis. A key component is the company's "Disease Classification Knowledge Graph," an AI-powered tool developed over eight years that has achieved significant market share. The system is designed to integrate seamlessly with various existing hospital information systems, enabling rapid deployment, often within 48 hours.

The firm has secured significant financial backing to fuel its growth. It completed a Series B+ funding round of 200 million RMB in July 2022, co-led by Haier Capital, with participation from existing investors Sinovation Ventures and Z-Link Capital, as well as new investor Constellation Capital. This followed a 200 million RMB Series B round in March 2022 and an undisclosed Series A from Sinovation Ventures in 2019.